tremelimumab; ticilimumab; CP-675,206; cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibody, recombinant -- Product Record

CTLA-4 Mab, rDNA/Pfizer

    Nomenclature:
      CTLA-4 Mab, rDNA/Pfizer [BIO]
      tremelimumab [USAN INN]
      ticilimumab [USAN INN; former, rescinded]
      immunoglobulin G2, anti-(human CTLA-4 (antigen)) (human monoclonal CP-675206 clone 11.2.1 heavy chain) disulfide with human monoclonal CP-675206 clone 11.2.1 light chain, dimer  [CAS]
      immunoglobulin G2, anti-(human Cytotoxic T-lymphocyte protein 4 (CD 152 antigen)) (human monoclonal CP-675206 clone 11.2.1 heavy chain) disulfide with human monoclonal CP-675206 clone 11.2.1 light chain, dimer [CAS]
      745013-59-6 [CAS RN]
      CP-675,206 [SY]
      CP-675206 [SY]
      cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibody, recombinant [SY]

    FDA Class:  Biologic BLA

Index Terms:

  • Product Class Index:
      antibodies (see also immune globulins; monoclonal antibodies)
      antibodies (see also immune globulins; monoclonal antibodies)
      biopharmaceutical products
      CYT-351 monoclonal antibody
      exempt from CBER lot release requirements
      immune globulin A (IgA)
      immune modulator
      monoclonal antibodies, recombinant
      recombinant DNA
  • Biological Index:
      cytomegalovirus major immediate early region 2 mRNA
      mammalian cell culture
  • Chemical Index:
  • Source/Host/Expression System: Mammalian mam
  • Regulatory/Status Index:
      apheresis (hemapheresis)
      North American coral snake
      North American coral snake
      EU000 Not yet/Never filed with EU
      UM999 Not Available/Not Marketed in US
      US001 FDA application expected
      EM999 Not Available/Not Marketed in EU